This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Thomas J. Dietz, Ph.D., Appointed To The Transcept Pharmaceuticals Board Of Directors

POINT RICHMOND, Calif., April 10, 2013 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that Thomas J. Dietz, Ph.D., Chairman and CEO of Waypoint Holdings, LLC, a financial holdings and services company, has joined the board of Transcept Pharmaceuticals as an independent director effective April 10, 2013.

Dr. Dietz has more than 20 years of experience supporting the biopharma industry and the institutional investment community.  Prior to his current role as Chairman and CEO of Waypoint Holdings, Dr. Dietz was co-CEO and then CEO and a Director of Pacific Growth Equities, LLC, a San Francisco-based investment bank and institutional brokerage firm from 2004 to 2009, when the firm was acquired by Wedbush Securities.  Dr. Dietz served as head of the investment banking division at Webush until November 2010.  Prior to becoming CEO at Pacific Growth, Dr. Dietz served as the firm's Director of Equities Research and was an award-winning biotechnology and biopharmaceutical analyst.  Dr. Dietz joined Pacific Growth in 1993.  Previously, he was a member of the research faculty in the Department of Medicine, University of California, San Francisco and the VA Medical Center.  Dr. Dietz is a member of several national societies and currently serves as Chairman of Galleon Pharmaceuticals, Inc. and Director of Glialogix, Inc. as well as on the boards of trustees of several non-profit organizations, including the West Bay Region board of the Sutter Health System that includes California Pacific Medical Center, San Francisco.  Dr. Dietz holds a Ph.D. in molecular biology and biochemistry from Washington University, St. Louis, and was a National Science Foundation Post-Doctoral Fellow. 

"The addition of Tom Dietz further enhances the Board's already strong pharmaceutical industry expertise," stated Glenn Oclassen, President and Chief Executive Officer.  "Tom brings a track-record of success and deep industry knowledge, and his viewpoint and advice will be important as we move through the next stage of our corporate development."

"Transcept Pharmaceuticals has a unique asset in Intermezzo, an experienced management team and a strong balance sheet," stated Dr. Dietz.  "I look forward to working with the Transcept board and team to capitalize upon these assets and to create shareholder value."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,037.97 -42.17 -0.23%
S&P 500 2,108.92 -8.77 -0.41%
NASDAQ 5,060.2460 -31.8390 -0.63%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs